Liver Injury/Regeneration News

Researchers found an association between sarcopenia and severity of fibrosis and steatosis among a Western population of patients with nonalcoholic fatty liver disease in a prospective study.

Patients with inflammatory bowel disease treated with thiopurines had a higher risk for hepatotoxicity if they had elevated 6-methylmercaptopurine ribonucleotide metabolite levels at 1 week after treatment began, according to recent study data.

Bristol-Myers Squibb announced it has entered an agreement with Nitto Denko Corporation that grants worldwide rights for the development and commercialization of Nitto’s investigational siRNA molecules targeting heat shock protein 47, including ND-L02-s0201, its lead investigational drug for the treatment of advanced liver fibrosis.

The Innovative Medicines Initiative SAFE-T Consortium and Critical Path Institute Predictive Safety Testing Consortium announced the FDA and EMA each issued a Biomarker Letter of Support for multiple liver safety biomarkers for potential use against drug-induced liver injury.

LAS VEGAS — Heavy alcohol drinkers presenting with the PNPLA3 G/G genotype who do not drink coffee on a regular basis have the greatest risk for alcoholic hepatitis, according to data presented during a plenary session at ACG 2016.

In China, Western medicine may contribute more to drug-induced liver injury than Chinese herbal medicine, according to findings published in the Journal of Gastroenterology and Hepatology.

Drinking at least 200 mL coffee a day may stave off the advancement of alcoholic liver disease and some cases of primary sclerosing cholangitis in patients with end-stage liver disease awaiting liver transplant, according to recent published findings. In addition, coffee consumption may increase survival post-transplant.

Blood microbiota dysbiosis and liver fibrosis existed concomitantly in patients with obesity, according to published findings.

FDA researchers developed a novel and effective tool to determine drug-induced liver injury risk and assist in choosing drug development candidates, according to research published in Hepatology.

Researchers at the University of Louisville received a federal grant of more than $11.5 million to study liver cancer, non-alcoholic steatohepatitis, nonalcoholic fatty liver disease, alcoholic liver disease and environmental toxicology and liver disease, and with future research focusing on infectious and viral liver disease and drug-induced liver injury, according to a press release.